Foghorn Therapeutics (FHTX) Cash & Equivalents (2019 - 2026)

Foghorn Therapeutics' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $87.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 43.65% year-over-year to $87.7 million; the TTM figure through Mar 2026 stood at $87.7 million (up 43.65% YoY), while the FY2025 annual figure was $80.9 million, up 45.84% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $87.7 million, up from $80.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $213.6 million in Q1 2022, with the low at $50.6 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $72.6 million (2025), against an average of $82.1 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 221.52% in 2022, then sank 76.3% in 2023.
• Foghorn Therapeutics' Cash & Equivalents stood at $52.2 million in 2022, then jumped by 53.86% to $80.3 million in 2023, then tumbled by 30.97% to $55.5 million in 2024, then jumped by 45.84% to $80.9 million in 2025, then grew by 8.39% to $87.7 million in 2026.
• Business Quant data shows FHTX's Cash & Equivalents at $87.7 million in Q1 2026, $80.9 million in Q4 2025, and $89.3 million in Q3 2025.